KDC-MN-026 – Kodiac biolabs

Plain-language summaryIntrigue 62 / 100

Aniracetam is a more potent racetam approved in Europe and Asia. It modulates AMPA glutamate receptors, slowing receptor desensitization, and is reported to have anxiolytic effects beyond cognition. Fat-soluble (best absorbed with food). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

Mechanistically interesting racetam with real AMPA PAM pharmacology but mature literature and limited modern research priority

Aniracetam is the racetam that actually has a mechanism worth talking about. Piracetam’s mode of action is still disputed; aniracetam’s AMPA positive allosteric modulation is real pharmacology, defined in the early 1980s by Cumin and colleagues at Roche and replicated across multiple labs since. The compound slows both deactivation and desensitization at synaptic AMPA receptors, extending open-channel time and strengthening excitatory postsynaptic currents in cortical and hippocampal circuits implicated in learning and memory. Thats a coherent substrate. What we like is that the mechanism is testable and has generated genuine downstream questions about receptor kinetics in synaptic plasticity.

The metabolite story complicates things in an interesting way. Parent aniracetam has about 0.2 percent oral bioavailability and a plasma half-life of roughly 35 minutes. The primary metabolite N-anisoyl-GABA accounts for 70 to 80 percent of metabolic output and carries its own pharmacological activity across cholinergic, dopaminergic, and serotonergic systems. When investigators run aniracetam in a cognition model, they’re looking at effects from the parent compound and at least three active breakdown products simultaneously. Scientifically interesting, experimentally messy.

The clinical record is modest by current standards. Two placebo-controlled multicenter trials in senile dementia of the Alzheimer type produced statistically significant improvements at 1500 mg per day, with one trial benchmarking aniracetam against piracetam directly. The open-label study in 276 patients added 12-month observational signal. These trials are old, and none of them would pass a modern pre-registration filter. The Japanese withdrawal, though likely commercially rather than safety-driven, doesnt help the optics when you’re reviewing the dossier fresh.

Here’s the honest case for deprioritizing aniracetam as a primary research target in 2026: the pure AMPA PAM story has moved on. Compounds like CX1739 and more selective ampakines are cleaner tools for isolating AMPA receptor biology with less metabolite noise. The multi-metabolite pharmacology makes mechanistic attribution genuinely difficult, the nootropic indication is crowded with better-evidenced alternatives, and four decades of literature means the compound has been mined. We know roughly what it does, which is actually a reason to study it less, not more.

There’s still a narrow use case. Labs working on AMPA receptor kinetics or the glutamate-to-monoamine cascade may want aniracetam as a historical comparator or a multi-target probe with a long preclinical record across cognitive, anxiolytic, and neuroprotective domains. The foundation is deep and real. But as a primary research investment in 2026, the signal-to-novelty ratio doesnt justify the prioritization over newer AMPA-targeting tools with cleaner pharmacokinetics.

Novelty: 28
Mechanism promise: 50
In-category differentiation: 38
Evidence quality: 45
Translational signal: 40
Research bench value: 42

Rationale Aniracetam earns genuine mechanistic credit as the first characterized AMPA PAM in the racetam class, with downstream multi-transmitter effects through active metabolites that are pharmacologically coherent but experimentally hard to attribute. Clinical evidence is real but old and underpowered by modern standards, and the AMPA PAM space has since produced more selective probes that reduce aniracetam’s bench value as a primary tool.

Pyrrolidinone-class positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with secondary cholinergic, dopaminergic, and serotonergic neuromodulatory activity

A lipophilic racetam nootropic developed at Hoffmann-La Roche as a cognition enhancer for cerebrovascular and neurodegenerative disorders, distinguished from piracetam by higher potency, oral lipophilicity, AMPA receptor positive allosteric modulation, and multi-target downstream activation of cholinergic, dopaminergic, and serotonergic neurotransmission through pharmacologically active metabolites.

Abstract

Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone; Ro 13-5057) is a lipophilic pyrrolidinone derivative of the racetam structural class, originally synthesized at Hoffmann-La Roche in the late 1970s as a more potent and centrally bioavailable analog of piracetam for the treatment of cognitive dysfunction associated with cerebrovascular disease and neurodegenerative dementia. The compound is classified as a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor, a mechanism that slows both channel deactivation and receptor desensitization at synaptic AMPA receptors, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic neurotransmission in cortical and hippocampal circuits critical for learning and memory [1, 2]. Beyond the direct AMPA receptor modulation, aniracetam and its principal active metabolite N-anisoyl-gamma-aminobutyric acid (N-anisoyl-GABA, which accounts for 70 to 80 percent of the metabolic disposition) exert downstream effects on multiple neurotransmitter systems: enhancement of acetylcholine release in the prefrontal cortex and hippocampus via group II metabotropic glutamate receptor modulation; site-specific activation of dopaminergic and serotonergic transmission in the mesocorticolimbic pathway through nicotinic acetylcholine receptor mechanisms; and anxiolytic activity mediated through an interaction between cholinergic, dopaminergic, and serotonergic systems [3, 4, 5]. The pharmacokinetic profile of aniracetam is characterized by rapid and complete gastrointestinal absorption, extremely low systemic bioavailability of the parent compound (approximately 0.2 percent) due to extensive first-pass hepatic hydrolysis, and a plasma elimination half-life of approximately 35 minutes [6, 7]. The parent compound is rapidly cleaved to yield three primary metabolites: N-anisoyl-GABA (70 to 80 percent), 2-pyrrolidinone (20 to 30 percent), and p-anisic acid (20 to 30 percent), each of which has been shown to contribute to the pharmacological activity profile [8]. The clinical evidence base for aniracetam derives principally from two double-blind, placebo-controlled multicenter trials in elderly patients with mild to moderate senile dementia of the Alzheimer type (SDAT), in which aniracetam at 1500 mg per day for six months produced statistically significant improvement in cognitive and psychobehavioral parameters relative to placebo and, in one trial, relative to piracetam at 2400 mg per day [9, 10]. A comparative open-label study in 276 patients with cognitive disorders demonstrated preservation of neuropsychological parameters for at least 12 months with aniracetam monotherapy and performance comparable to or exceeding cholinesterase inhibitor monotherapy in mildly demented patients [11]. Preclinical pharmacology is extensive and demonstrates cognitive enhancement in scopolamine-induced amnesia, cerebral ischemia, and age-related cognitive decline models; anxiolytic activity in elevated plus-maze, conditioned fear, and social interaction paradigms; neuroprotection against excitotoxicity and ischemic injury; and activation of brain-derived neurotrophic factor synthesis [12, 13, 14]. The compound was marketed as a prescription medicine in Japan (Draganon, subsequently withdrawn), in Italy (Ampamet), and in Greece (Memodrin, Referan) for cognitive impairment associated with cerebrovascular disease and neurodegenerative conditions. It is not approved by the United States Food and Drug Administration and is not a controlled substance in the United States, where it is sold as a research compound. This monograph reviews the chemistry, synthesis, and structural pharmacology of aniracetam; the multi-target mechanism of action spanning AMPA receptor modulation, metabotropic glutamate receptor effects, and monoaminergic neuromodulation; the comprehensive pharmacokinetic record including active metabolite characterization; the preclinical pharmacology across cognitive, anxiolytic, and neuroprotective domains; the clinical evidence base in dementia and cognitive impairment; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety; and a comparative assessment of five racetam and ampakine alternatives against aniracetam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1426Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-026

Aniracetam

Abstract

Read the full monograph